dc.contributor.author | Rao, Deepa A. | |
dc.contributor.author | Forrest, M. Laird | |
dc.contributor.author | Alani, Adam W.G. | |
dc.contributor.author | Kwon, Glen S. | |
dc.contributor.author | Robinson, Joseph R. | |
dc.date.accessioned | 2017-02-23T20:42:29Z | |
dc.date.available | 2017-02-23T20:42:29Z | |
dc.date.issued | 2010-04 | |
dc.identifier.citation | RAO, D. A., FORREST, M. L., ALANI, A. W. G., KWON, G. S., & ROBINSON, J. R. (2010). Biodegradable PLGA Based Nanoparticles for Sustained Regional Lymphatic Drug Delivery. Journal of Pharmaceutical Sciences, 99(4), 2018–2031. http://doi.org/10.1002/jps.21970 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23241 | |
dc.description.abstract | The purpose of this work is to evaluate biodegradable drug carriers with defined size, hydrophobicity, and surface charge density for preferential lymphatic uptake and retention for sustained regional drug delivery. PLGA–PMA:PLA-PEG (PP) nanoparticles of defined size and relative hydrophobicity were prepared by nanoprecipitation method. These were compared with PS particles of similar sizes and higher hydrophobicity. PLGA–PMA:PLGA-COOH (PC) particles at 80:20, 50:50, and 20:80 ratios were prepared by nanoprecipitation for the charge study. Particle size and zeta potential were characterized by dynamic light scattering and laser doppler anemometry, respectively. Particles were administered in vivo to rats subcutaneously. Systemic and lymph node uptake was evaluated by marker recovery. Lymphatic uptake and node retention of PP nanoparticles was shown to be inversely related to size. Lymphatic uptake and node retention of PP particles, as compared to PS particles, was shown to be inversely related to hydrophobicity. Lastly, lymphatic uptake and node retention of PC nanoparticles were directly related to the anionic charge on the particles. In vivo lymphatic uptake and retention in a rat model indicates that the 50 nm PP particles are ideal for sustained regional delivery into the lymphatics for prevention/treatment of oligometastases. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | © 2009 Wiley-Liss, Inc. and the American Pharmacists Association | en_US |
dc.subject | PLGA | en_US |
dc.subject | Lymphatic transport | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | Biocompatibility | en_US |
dc.subject | Distribution | en_US |
dc.title | Biodegradable PLGA Based Nanoparticles for Sustained Regional Lymphatic Drug Delivery | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Forrest, M. Laird | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.oanotes | Per Sherpa Romeo on 02/23/2017: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions: Authors pre-print on any website, including arXiv and RePEC Author's post-print on author's personal website immediately Author's post-print on open access repository after an embargo period of between 12 months and 48 months Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months Author's post-print may be used to update arXiv and RepEC Publisher's version/PDF cannot be used Must link to publisher version with DOI Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License | en_US |
dc.identifier.doi | 10.1002/jps.21970 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | |